Benzinga | Nov 5, 2021 10:39AM EDT

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $617

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $571 to $617.